• P/Q-Type Calcium Channels Mediate Nicotinic Activation in Ca

  2026-08-04

  This study demonstrates that presynaptic and postsynaptic responses of cardiac vagal neurons to nicotinic stimulation are critically dependent on agatoxin-IVA-sensitive (P/Q-type) voltage-dependent calcium channels. These findings clarify the mechanistic underpinnings of neurotransmission in the cardiac vagal circuit and offer precise molecular targets for dissecting calcium-dependent processes in neurocardiac physiology.

• Leupeptin Hemisulfate Salt: Advanced Workflows in Protease R

  2026-08-04

  Leupeptin hemisulfate salt empowers researchers to precisely control serine and cysteine protease activity in complex biochemical and virological workflows. This article details actionable protocol enhancements, troubleshooting strategies, and direct applications in protein degradation and viral inhibition—bridging mechanistic insight with practical assay optimization.

• Optimized hGBA1 mRNA Restores Lysosomal GCase in Gaucher Mod

  2026-08-03

  This study presents a rationally engineered human GBA1 mRNA that delivers markedly enhanced and sustained β-glucocerebrosidase (GCase) activity in cellular and animal Gaucher disease models. The findings demonstrate a promising mRNA-LNP therapeutic approach, with implications for more effective and durable correction of lysosomal dysfunction beyond current enzyme replacement therapies.

• Q-VD-OPh in Senescence-Apoptosis Crosstalk: Next-Gen Strateg

  2026-08-03

  Explore how Q-VD-OPh, a potent pan-caspase inhibitor, redefines apoptosis research by bridging senescence and cell death mechanisms. This article uniquely focuses on translational strategies for eliminating persistent senescent cells and optimizing cell viability in complex disease models.

• 25-Hydroxycholesterol Drives AMPK-Mediated Macrophage Reprog

  2026-08-02

  Xiao et al. (2024) reveal that 25-hydroxycholesterol (25HC) accumulation in tumor-associated macrophages (TAMs) triggers lysosomal AMPKα activation through a GPR155-mTORC1 pathway, leading to immunosuppressive programming via STAT6 phosphorylation. This mechanistic insight redefines the metabolic control of macrophage function in the tumor microenvironment and highlights CH25H as a potential immunometabolic checkpoint.

• Angiotensin I: Mechanistic Insights and Translational Levera

  2026-08-01

  This thought-leadership article examines Angiotensin I as a mechanistic and strategic fulcrum in renin-angiotensin system research, from molecular signaling to translational models and antiviral intersections. Grounded in recent mechanistic advances, it offers protocol parameters, competitive analysis, and a visionary outlook for researchers seeking to bridge cardiovascular and emerging viral research.

• Metabolic Sensitization of Tumor Cells to Ferroptosis and Cu

  2026-07-31

  This study introduces an innovative metabolic intervention that synchronously sensitizes tumor cells to both ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The resulting boost in regulated cell death and anti-tumor immunity provides a new platform for advancing cancer therapies based on iron and copper dysregulation.

• TPCA-1: Precision IKK-2 Inhibitor for Translational Inflamma

  2026-07-31

  TPCA-1, a highly selective IKK-2 inhibitor from APExBIO, empowers researchers to dissect the NF-κB pathway with unparalleled specificity in inflammation and rheumatoid arthritis models. This article translates the latest mechanistic insights and workflow optimizations into actionable guidance for advanced cytokine inhibition studies.

• Prion-Controlled Mutagenesis Enables Rapid Fungal Adaptation

  2026-07-30

  This study demonstrates that prion-based self-assembly of DNA repair proteins dynamically tunes mutation rates in yeast, enabling rapid adaptation under selective stress. The work reveals a heritable, reversible epigenetic mechanism for genome diversification with significant implications for understanding drug resistance and adaptive evolution.

• 25-Hydroxycholesterol, AMPK, and Macrophage Reprogramming in

  2026-07-30

  Xiao et al. (2024) reveal that 25-hydroxycholesterol accumulation in tumor-associated macrophages drives immunosuppressive programming by activating the AMPKα–STAT6 axis via a lysosomal mechanism. Disrupting this pathway reshapes the tumor immune microenvironment and enhances anti-tumor responses, suggesting novel strategies for targeting metabolic checkpoints in cancer.

• Phenylmethanesulfonyl Fluoride: Transforming Protease Inhibi

  2026-07-29

  Explore how Phenylmethanesulfonyl fluoride (PMSF) elevates protein extraction integrity, empowers translational researchers, and enables advanced mechanistic studies, with a strategic emphasis on serine protease inhibition and robust Western blot workflows.

• Perifosine (KRX-0401): Strategic Applications in Akt/mTOR Mo

  2026-07-29

  Explore how Perifosine (KRX-0401), a synthetic Akt inhibitor, empowers translational researchers to dissect apoptosis and stress signaling in cancer and neuroprotection. This article delivers mechanistic insights, protocol guidance, and strategic outlooks grounded in recent evidence, with a focus on the PI3K/Akt/mTOR axis and its emerging relevance across oncology and neuroscience.

• IBDV VP3 Protein Drives IRF7 Degradation to Facilitate Repli

  2026-07-28

  This study uncovers how the infectious bursal disease virus (IBDV) uses its VP3 protein to target and degrade interferon regulatory factor 7 (IRF7), suppressing type I interferon responses and enhancing viral replication in chicken cells. These findings illuminate a novel mechanism of immune evasion with implications for understanding antiviral defense and developing targeted interventions.

• Metabolic Intervention Enhances Ferroptosis and Cuproptosis

  2026-07-28

  This study introduces a nanosystem-based metabolic intervention that synchronously sensitizes tumor cells to ferroptosis and cuproptosis by targeting glycolysis and NAD+ metabolism. The approach not only amplifies regulated cell death but also strengthens anti-tumor immunity, providing a technical foundation for future combination strategies in cancer therapy.

• Nuclear cGAS Restricts L1 Retrotransposition via CHK2-TRIM41

  2026-07-27

  This study uncovers how nuclear cGAS suppresses LINE-1 (L1) retrotransposition by facilitating TRIM41-mediated degradation of ORF2p, with CHK2-dependent phosphorylation of cGAS as a key regulatory step. These findings illuminate a novel genome stability mechanism with implications for aging and cancer biology.

15259 records 1/1018 page Next 12345 下5页 Last page